AMG 553

AMG 553 is an investigational autologous chimeric antigen receptor (CAR) T-cell immunotherapy developed for the treatment of acute myeloid leukemia (AML). It consists of a patient’s own T lymphocytes that are genetically engineered ex vivo to express a CAR targeting FMS-like tyrosine kinase 3 (FLT3), a protein expressed on the surface of most AML cells. The CAR construct includes a single-chain variable fragment that binds FLT3, along with CD28 costimulatory and CD3 zeta activation domains. By targeting FLT3, AMG 553 aims to induce selective cytotoxicity against AML cells while sparing most normal tissues, as FLT3 expression outside hematopoietic stem and progenitor cells is limited or intracellular. Nonclinical studies support its potential efficacy and safety in selectively eliminating FLT3-positive leukemic cells[1][2][3][4][5][6][7]. It is being developed by Amgen.

Other names

anti-FLT3 CAR-Tanti-FLT-3 CAR-Tanti-FLT 3 CAR-TFLT3-CD28-CD3zFLT-3-CD28-CD3zFLT 3-CD28-CD3zFLT3-directed CAR T-cell therapyFLT-3-directed CAR T-cell therapyFLT 3-directed CAR T-cell therapyanti-FLT3 CARanti-FLT-3 CARanti-FLT 3 CAR